Information Provided By: 
Fly News Breaks for April 24, 2018
TSRO
Apr 24, 2018 | 09:46 EDT
After Tesaro announced top-line data from the QUADRA study of Zejula in heavily pre-treated ovarian cancer patients, H.C. Wainwright analyst Edward White said he views the data positively and continues to think that Zejula in combination with Tesaro's IO candidates could become commercially successful therapies and offer upside to the company's stock. The analyst, who thinks investors are giving Tesaro minimal credit for its IO platform, maintains a Buy rating and $108 price target on Tesaro shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
